Approval Granted for VIZZ Eye Drops: Enhances Clarity of Near Vision for a Duration of Ten Hours
The US market is on the brink of a major breakthrough in eye care innovation, with the impending release of VIZZ, an FDA-approved eye drop designed to improve near vision without the need for reading glasses. Developed by LENZ Therapeutics, VIZZ is expected to hit the market as early as October 2025, with commercial availability broadly by the middle of the fourth quarter of 2025 [1][2].
VIZZ is the first and only FDA-approved eye drop containing aceclidine 1.44%, a unique compound that works by contracting the iris sphincter muscle, creating a pinhole effect that increases depth of focus [1][2][3][4]. This pinhole effect allows users to see nearby objects more clearly without compromising distance vision.
Safety was a primary concern during the testing of VIZZ, and across more than 30,000 treatment days, no serious adverse events were reported [1]. The effect of VIZZ takes about 30 minutes to occur, and it lasts up to 10 hours, offering a full day of improved near vision from a single dose [1][2].
Presbyopia, a condition affecting over 128 million adults in the US, is expected to be the primary target for VIZZ. Presbyopia is a natural age-related condition that makes it difficult to focus on near objects, often requiring the use of reading glasses [5].
Results from three Phase 3 clinical trials with over 680 participants show that VIZZ consistently aids patients in reading smaller print and performing close-up tasks with ease [1]. The use of VIZZ does not cause a myopic shift, making it a safe and effective solution for those struggling with presbyopia.
VIZZ offers a convenient, non-invasive alternative to reading glasses, providing a much-needed solution for millions of people. Eye care professionals and patients can expect to see VIZZ becoming available in the US market mostly starting from late 2025, specifically from October for samples and broadly by late fall to early winter 2025.
References: [1] PR Newswire. (2025, July 31). LENZ Therapeutics Announces FDA Approval of VIZZ for Presbyopia. PR Newswire. https://www.prnewswire.com/news-releases/lenz-therapeutics-announces-fda-approval-of-vizz-for-presbyopia-301557194.html [2] Lenz Therapeutics. (2025, July 31). Lenz Therapeutics Announces FDA Approval of VIZZ for Presbyopia. Lenz Therapeutics. https://www.lenztx.com/news/lenz-therapeutics-announces-fda-approval-of-vizz-for-presbyopia/ [3] Lenz Therapeutics. (2025, August 1). Frequently Asked Questions About VIZZ. Lenz Therapeutics. https://www.lenztx.com/patients/faqs/ [4] Lenz Therapeutics. (2025, August 1). VIZZ. Lenz Therapeutics. https://www.lenztx.com/patients/vizz/ [5] National Institute on Aging. (2021, January). Presbyopia: Overview. National Institute on Aging. https://www.nia.nih.gov/health/presbyopia-overview
Science has made a significant advancement in the health and wellness sector, particularly in medical-conditions related to eyesight, with the FDA's approval of VIZZ, an eye drop developed by LENZ Therapeutics. VIZZ addresses presbyopia, a common age-related condition affecting millions of adults in the US, offering a non-invasive, convenient alternative to reading glasses.
